Novo, Lilly's shares drop
Digest more
On the face of it, the chances of success appear slim: the vast majority of experimental drugs for Alzheimer’s have ended in ...
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
In a significant stride for chronic disease management, FDA granted approvals for Roche’s lupus nephritis treatment and Novo Nordisk’s cardiovascular-risk-reducing oral semaglutide for adults with ...
Shares of Danish pharmaceutical giant Novo Nordisk are trading lower Friday morning, continuing an after-hours slide that ...
The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat Type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback